Biofrontera AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
June 18, 2019 at 04:05 pm
Share
DGAP Voting Rights Announcement: Biofrontera AG
Biofrontera AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
18.06.2019 / 17:00
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Notification of Major Holdings
1. Details of issuer
Name:
Biofrontera AG
Street:
Hemmelrather Weg 201
Postal code:
51377
City:
Leverkusen Germany
Legal Entity Identifier (LEI):
391200D6GFSVFGFQTL13
2. Reason for notification
X
Acquisition/disposal of shares with voting rights
Acquisition/disposal of instruments
Change of breakdown of voting rights
Other reason:
3. Details of person subject to the notification obligation
Natural person (first name, surname): Wilhelm K. T. Zours Date of birth: 28 Jul 1961
4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
DELPHI Unternehmensberatung Aktiengesellschaft; SPARTA AG
5. Date on which threshold was crossed or reached:
13 Jun 2019
6. Total positions
% of voting rights attached to shares (total of 7.a.)
% of voting rights through instruments (total of 7.b.1 + 7.b.2)
Total of both in % (7.a. + 7.b.)
Total number of voting rights pursuant to Sec. 41 WpHG
New
25.26 %
0.00 %
25.26 %
44,632,674
Previous notification
23.05 %
0.00 %
23.05 %
/
7. Details on total positions a. Voting rights attached to shares (Sec. 33, 34 WpHG)
ISIN
Absolute
In %
Direct (Sec. 33 WpHG)
Indirect (Sec. 34 WpHG)
Direct (Sec. 33 WpHG)
Indirect (Sec. 34 WpHG)
DE0006046113
0
11,273,828
0.00 %
25.26 %
Total
11,273,828
25.26 %
b.1. Instruments according to Sec. 38 (1) no. 1 WpHG
Type of instrument
Expiration or maturity date
Exercise or conversion period
Voting rights absolute
Voting rights in %
0
0.00 %
Total
0
0.00 %
b.2. Instruments according to Sec. 38 (1) no. 2 WpHG
Type of instrument
Expiration or maturity date
Exercise or conversion period
Cash or physical settlement
Voting rights absolute
Voting rights in %
0
0.00 %
Total
0
0.00 %
8. Information in relation to the person subject to the notification obligation
Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X
Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:
Name
% of voting rights (if at least 3% or more)
% of voting rights through instruments (if at least 5% or more)
Total of both (if at least 5% or more)
Wilhelm K. T. Zours
%
%
%
DELPHI Unternehmensberatung Aktiengesellschaft
12.44 %
%
12.44 %
VV Beteiligungen Aktiengesellschaft
%
%
%
Deutsche Balaton Aktiengesellschaft
%
%
%
ABC Beteiligungen AG
%
%
%
Wilhelm K. T. Zours
%
%
%
DELPHI Unternehmensberatung Aktiengesellschaft
12.44 %
%
12.44 %
VV Beteiligungen Aktiengesellschaft
%
%
%
Deutsche Balaton Aktiengesellschaft
%
%
%
Prisma Equity AG
%
%
%
Wilhelm K. T. Zours
%
%
%
DELPHI Unternehmensberatung Aktiengesellschaft
12.44 %
%
12.44 %
VV Beteiligungen Aktiengesellschaft
%
%
%
Deutsche Balaton Aktiengesellschaft
%
%
%
Deutsche Balaton Biotech AG
%
%
%
Wilhelm K. T. Zours
%
%
%
DELPHI Unternehmensberatung Aktiengesellschaft
12.44 %
%
12.44 %
VV Beteiligungen Aktiengesellschaft
%
%
%
Deutsche Balaton Aktiengesellschaft
%
%
%
SPARTA AG
6.79 %
%
6.79 %
9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)
Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:
Proportion of voting rights
Proportion of instruments
Total of both
%
%
%
10. Other explanatory remarks:
Date
14 Jun 2019
18.06.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Biofrontera AG is a Germany-based biopharmaceutical company. The Company develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells; and Belixos, a dermatological cream with herbal ingredients for the care of itching, inflamed and flaky skin and conditions such as insect bites, burns, neurodermatitis and psoriasis. The Company is also engaged in clinical development of two drug candidates: BF-derm1, a tablet with inhibitor blocking the synthesis of histamine in cells, a cause of allergic reactions; and BF1, a selective serotonin receptor to prevent migraines. The Company operates five wholly owned subsidiaries, notably Biofrontera Inc in the United States. Its main shareholder is MM Familien KG.
Biofrontera AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution